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Specific inhibitors of cyclooxygenase 2 (COX-2)
have been approved for the treatment of osteoarthritis
and rheumatoid arthritis. Unlike nonsteroidal anti-
inflammatory drugs, specific COX-2 inhibitors do not
inhibit platelet activation. However, these agents signif-
icantly reduce systemic production of prostacyclin. As a
result, theoretical concerns have been raised that spe-
cific COX-2 inhibitors could shift the hemostatic bal-
ance toward a prothrombotic state. Patients with con-
nective tissue diseases (CTD), who may be predisposed
to vasculopathy and thrombosis, often have arthritis or
pain syndromes requiring treatment with antiinflamma-
tory agents. Herein we describe 4 patients with CTD
who developed ischemic complications after receiving
celecoxib. All patients had a history of Raynaud’s phe-
nomenon, as well as elevated anticardiolipin antibodies,
lupus anticoagulant, or a history compatible with an-
tiphospholipid syndrome. It was possible to measure a
urinary metabolite of thromboxane A2 in 2 of the
patients as an indicator of in vivo platelet activation,
and this was markedly elevated in both. In addition, the
patients had evidence of ongoing inflammation as indi-
cated by elevated erythrocyte sedimentation rate, hypo-
complementemia, and/or elevated levels of anti-DNA
antibodies. The findings in these 4 patients suggest that
COX-2 inhibitor–treated patients with diseases that
predispose to thrombosis should be monitored carefully
for this complication.
Prostaglandins (PG) and thromboxane (TX) are
regulators of platelet and endothelial cell function.
Activated platelets synthesize TXA2, which is a potent
platelet aggregant and vasoconstrictor. PGI2, which is
synthesized primarily by endothelial cells, inhibits plate-
let activation by elevating platelet cyclic AMP and
induces vasodilation. There is evidence that endogenous
PGI2 has antithrombotic properties. Infusion of PGI2
and enhancement of endogenous PGI2 also provide
antiplatelet activity (1).
A multienzyme pathway that includes the cyclo-
oxygenase (COX) enzymes is responsible for synthesis of
prostanoids. There are 2 COX isoforms, COX-1 and
COX-2. COX-1 is constitutively expressed in most tis-
sues and is the only isoform in platelets (2). The
antiplatelet effects of aspirin and other nonsteroidal
antiinflammatory drugs (NSAIDs) are mediated
through inhibition of COX-1–dependent TXA2 produc-
tion (3). COX-2 expression is induced by inflammation
and tissue injury (4). The majority of the antiinflamma-
tory, analgesic, and antipyretic actions of NSAIDs are
due to inhibition of COX-2 (4). Specific COX-2 inhibi-
tors developed for use in patients with osteoarthritis,
rheumatoid arthritis, and pain have efficacy similar to
that of nonselective NSAIDs that inhibit both COX
isoforms.
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Inhibition of both COX-1 and COX-2 by anti-
inflammatory doses of aspirin and NSAIDs leads to a
simultaneous decrease in platelet TXA2 and endothe-
lial cell PGI2, resulting in a balanced reduction of
prostanoids with opposing actions. In contrast, spe-
cific COX-2 inhibitors have no effect on platelet
TXA2, and thus do not inhibit platelet function (5,6).
Since specific COX-2 inhibitors block production of
systemic PGI2, the question has been raised as to
whether these agents may be prothrombotic (7,8).
Herein we report the cases of 4 patients with connec-
tive tissue diseases (CTD) in whom administration of
Figure 1. A, Early-phase (left panel) and late-phase (right panel) lower extremity angiography of
the left lower leg of patient 1, demonstrating abrupt occlusion of the anterior tibial artery at the
level of the ankle. There is little collateral flow and no perfusion distal to the metatarsals. B, Dorsal
aspect of the left foot of patient 1, demonstrating ischemic change.
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celecoxib, a specific COX-2 inhibitor, was temporally
associated with thrombosis.
CASE REPORTS
Patient 1. Patient 1, a 42-year-old woman, was
admitted to the University of Michigan Medical Center
(UMMC) with a painful, cold, and cyanotic left foot. She
had a 23-year history of arthritis, Raynaud’s phenome-
non (RP), and fatigue treated intermittently with pred-
nisone and hydroxychloroquine (HCQ). She had a 45–
pack-year smoking history. Two weeks prior to
admission, celecoxib in 200-mg capsules had been pre-
scribed, to be taken up to twice daily on an as-needed
basis. Her symptoms had developed acutely after 2 doses
of celecoxib. She presented to an outside hospital, where
angiography revealed diffuse aortoiliac and common
femoral atherosclerotic disease, chronic occlusion of the
left posterior tibial and peroneal arteries at the level of
the mid-calf, and abrupt occlusion of the anterior tibial
artery at the level of the ankle, consistent with acute
thromboembolic disease (Figure 1A). She was adminis-
tered 1 dose of intravenous methylprednisolone (IV
MP). Treatment with unfractionated heparin was begun,
and she was transferred to UMMC.
On admission, the patient’s left forefoot showed
blue mottling (Figure 1B) and was cool to touch. The
dorsalis pedis and posterior tibial pulses were dimin-
ished. Heparin and IV MP were continued, and treat-
ment with an oral calcium channel blocker was added to
alleviate vasospasm. Findings on a surface echocardio-
gram were normal. The results of serologic and coagu-
lation studies are presented in Table 1. Urokinase
infusion failed to reestablish blood flow, and the patient
underwent an embolectomy, which resulted in partial
restoration of arterial flow. Just prior to discharge, a
spot urine collection was obtained for analysis of the
urinary metabolites of TXA2 (11-dehydro TXB2) and
PGI2 (2,3-dinor-6-keto PGF1a) (Table 2). The patient
was discharged on a regimen of daily warfarin, pred-
nisone, and HCQ. At followup 1 month after discharge,
arterial flow to the left forefoot remained diminished,
with a pulse detectable only by doppler. She had devel-
oped gangrene of the distal half of the left great toe and
an ischemic ulcer on the dorsum of the foot.
Patient 2. Patient 2 was a 37-year-old woman who
was admitted to UMMC with pain and cyanosis of the
toes of the right foot and interdigital ulceration. Sys-
temic lupus erythematosus (SLE) had been diagnosed 7
years previously. Her disease was characterized by RP,
arthritis, sicca symptoms, and, more recently, cerebritis
necessitating monthly treatment with IV cyclo-
phosphamide. Other medications included daily MP (16
mg) and HCQ (400 mg). She had previously undergone
right upper extremity sympathectomy for refractory RP.
Celecoxib (100 mg twice daily) had been prescribed 3
weeks prior to admission. Within 1 week of beginning
this treatment, she developed swelling of the right foot.
After an additional week of treatment, she developed
Table 1. Summary of the results of serologic and coagulation studies in the 4 patients*
Patient 1 Patient 2 Patient 3 Patient 4
ANA, titer and pattern .1:2,560, speckled† .1:2,560, homogeneous† 1:2,560, nucleolar† 1:160, homogeneous†
Anti-dsDNA, IU/ml (normal 0.0–0.7) 52.1† 129.9† 2 17.3†
ENA Sm1, RNP2, Sm2, RNP2, Sm2, RNP1, Sm2, RNP2,
Ro/SSA2, Ro/SSA1, Ro/SSA1, Ro/SSA2,
La/SSB2 La/SSB1 La/SSB2 La/SSB2
Anti–Scl-70 1† 2 ND ND
RF, IU/ml (normal 0–30) 250† ND ND ,20
C3, mg/dl (normal 83–240) 66† 69† 55.6† 61†
C4, mg/dl (normal 13–60) ,10† 12† 12† 13
ESR, mm/hour (normal 0–20) 67† 17 100† 91†
CRP, mg/dl (normal 0.0–0.6) 1.6† 0.9† ND 2.1†
IgG ACA, GPL (normal 0–22) 52† 42† 2 10
IgM ACA, MPL (normal 0–10) 25† 2 2 2
DRVVT, seconds (normal 25.9–34.7) ND 33.9 ND 37.2†
PT, seconds (normal 9.3–10.9) 11.9†, INR 1.2
(on heparin)
9.6, INR 1.0 18.3†, INR 2.6
(on warfarin)
9.6, INR 1.0
APTT, seconds (normal 20.3–27.4) 84† 23.4 40† 20.1
(on heparin)
* ANA 5 antinuclear antibody; anti-dsDNA 5 anti–double-stranded DNA; ENA 5 extractable nuclear antigen; ND 5 not done; RF 5 rheumatoid
factor; ESR 5 erythrocyte sedimentation rate; CRP 5 C-reactive protein; ACA 5 anticardiolipin antibody; DRVVT 5 dilute Russell viper venom
time; PT 5 prothrombin time; INR 5 international normalized ratio; APTT 5 activated partial thromboplastin time.
† Abnormal value.
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purplish discoloration of the toes of the right foot, with
pain and swelling that prompted her to discontinue the
celecoxib. She was admitted because of worsening pain
and cyanosis.
On presentation, the dorsalis pedis pulses were
strong and equal bilaterally. There was no lower extrem-
ity edema. The toes of the right foot were cyanotic, and
there were ulcerations in the third and fourth interdigital
spaces. Serologic and coagulation results are shown in
Table 1. She was treated with IV MP, 1 gm daily for 3
consecutive days, and discharged on a regimen of oral
MP 20 mg and aspirin 325 mg daily, later reduced to 80
mg daily. With aspirin treatment, measured values of
urinary PGI2 and TXA2 metabolites were within the
normal range, as expected (data not shown). After the
patient failed to improve clinically, she was readmitted 2
weeks later to receive an IV bolus of cyclophosphamide.
On followup 2 weeks later, the ulcerated areas had
healed, but there was persistent digital ischemia with
constant pain, bluish discoloration, and coolness to
touch.
Patient 3. This patient, a 56-year-old woman with
systemic sclerosis (SSc) and lupus anticoagulant (LAC),
was admitted to the Medical University of South Caro-
lina with shortness of breath. She was diagnosed as
having SSc associated with pulmonary hypertension and
RP in 1995. She developed an ulnar artery thrombosis in
May 1997 and was prescribed warfarin after the LAC
was detected. Her prothrombin time international nor-
malized ratio was maintained in the 2.0–2.5 range rather
than the recommended range of .3 since she had
previously had excessive vaginal and gastrointestinal
bleeding. In April 1999, she developed leg pain and was
prescribed celecoxib (200 mg once or twice daily). After
2 days, she developed dyspnea. She presented to the
emergency room 2 days after the dyspnea developed.
A V/Q scan identified at least 3 mismatched
defects in the right upper lobe, right lower lobe, and left
upper lobe, leading to interpretation as a high probabil-
ity for pulmonary embolus. Cardiac and lower extremity
ultrasound failed to reveal a thrombotic source. She was
treated with heparin, and a followup V/Q scan before
discharge revealed no mismatched defects. Findings of
serologic and coagulation studies are shown in Table 1.
After resolution of the thrombus, discontinuation of
celecoxib and heparin, and reinitiation of warfarin, spot
urine samples were collected for measurement of uri-
nary metabolites of TXA2 and PGI2 (Table 2).
Patient 4. Patient 4, a 41-year-old woman with a
history of SLE, was admitted to UMMC with a cold,
painful, cyanotic right foot. The patient had an earlier
history of bilateral deep venous thromboses, a miscar-
riage occurring at 7 months into the pregnancy, and
elevated IgG anticardiolipin antibody (ACA). She had
been treated with warfarin for ;7 years, but it had been
discontinued 10 years prior to admission. Past manifes-
tations of SLE also included lupus nephritis diagnosed
by renal biopsy, myositis, RP, and synovitis. She had
been treated with methotrexate (15 mg/week) and pred-
nisone (10 mg/day). Her antiinflammatory drug was
changed to celecoxib (200 mg twice daily) 5 months prior
to admission. Approximately 2 months after the initia-
tion of celecoxib treatment she presented to the emer-
gency room with bluish mottling and pain in her right
foot. The symptoms were attributed to vasculitis. The
next month she again developed bluish discoloration of
her right foot with ulcer formation on the toes. She was
admitted to UMMC with a diagnosis of vasculitis.
Serologic and coagulation findings are shown in
Table 1. Ankle–brachial arterial indices were normal,
and a surface echocardiogram failed to reveal valvular
vegetations. The patient was treated with IV MP and
discharged on a regimen of prednisone in an increased
dosage (60 mg/day). Her treatment with celecoxib was
continued. She returned 1 week later with an ischemic,
pulseless right foot. Arteriography revealed a large,
elongated thrombus of the distal right common iliac
artery extending to and occluding the right internal iliac
Table 2. Urinary metabolites of systemic thromboxane A2 (TXA2) and prostaglandin I2 (PGI2)*
Patient 1 Patient 3
Urine 11-dehydro TXB2 1.89 ng/mg creatinine (normal ,1.00;
matched control 0.18)†
4.11 6 0.17 ng/mg creatinine
(normal ,0.65)
Urine 2,3-dinor-6-keto PGF1a 0.348 ng/mg creatinine (normal ,0.200;
matched control 0.025)
0.472 6 0.032 ng/mg creatinine
(normal ,0.29)
* Urine 11-dehydro TXB2 is the metabolite of extrarenal TXA2, and urinary 2,3-dinor-6-keto PGF1a is the metabolite of PGI2 produced outside the
kidney. Metabolites were measured by gas chromatography negative ion chemical ionization mass spectometry using authentic deuterated standards
(8). Patient 2 had been treated with low-dose aspirin, and values were in the normal range (data not reported). Urine for measurement of eicosanoid
metabolites was unavailable from patient 4.
† Control was matched by age and sex.
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artery. Occlusive thrombus was also present within the
distal right popliteal artery above the level of the knee.
Occlusive emboli involved the proximal right anterior
tibial, proximal peroneal, and proximal posterior tibial
arteries. There was no evidence of atherosclerotic dis-
ease. The patient was treated with thrombolytic infusion
therapy that resulted in some improvement; however,
surgical embolectomy was needed for restoration of
blood flow to the pedal vessels. Long-term warfarin
therapy was instituted prior to discharge.
DISCUSSION
This is the first report of thrombosis temporally
associated with administration of a specific COX-2
inhibitor (Table 3). The findings in these patients raise
the possibility that specific inhibition of COX-2 may
shift the hemostatic balance toward a prothrombotic
state in some patients. Specific inhibition of COX-2
decreases systemic PGI2, a significant proportion of
which is likely derived from the vascular endothelium
(7,8). PGI2 is a potent inhibitor of platelet function and
vascular tone (9), and decreased PGI2 production results
in the loss of a natural inhibitor of platelet activation.
Reduced PGI2 synthesis may act in concert with other
thrombotic risk factors occurring in a given patient to
precipitate acute vascular occlusion. This risk is likely
increased in patients whose platelet TXA2 synthesis is
already elevated.
Recent studies have shown that COX-2 is the
primary isoform responsible for the systemic biosynthe-
sis of PGI2 under physiologic conditions in humans (7,8).
This finding is consistent with in vitro data showing that
laminar, but not turbulent, shear stress induces selective
and sustained up-regulation of COX-2 in macrovascular
endothelial cells (10). Endothelial COX-2 expression
may also be increased in the presence of atherosclerotic
disease or proinflammatory cytokines, both of which can
be present in patients with CTD (11,12).
The influence of celecoxib on PGI2 production in
these patients occurred in the context of risk factors that
collectively predispose to thrombosis. Two patients had
elevated levels of ACA, 1 had LAC, and 1 had previously
elevated ACA with a history of thrombosis and miscar-
riage typical of the antiphospholipid syndrome (APS).
ACA and LAC are part of the spectrum of antiphospho-
lipid antibodies (aPL) that predispose to arterial and
venous thrombosis (13). The mechanism of vascular
thrombosis in patients with APS is not completely
known, but it is likely multifactorial (13). There is
evidence that alterations of eicosanoid generation may
be involved. Patients with aPL have increased TXA2
levels, suggesting a role for platelet activation in the
pathophysiology of thrombotic events (13,14). In fact, an
imbalance of thromboxane/prostacyclin biosynthesis
based on measurement of urinary metabolites has been
previously proposed as being crucial to development of
thrombosis in patients with LAC (15).
In a recent study of patients with SLE, enhanced
excretion of urinary TXA2 metabolites was highly asso-
ciated with the presence of aPL and evidence of endo-
thelial perturbation, as determined by elevated urinary
excretion of von Willebrand factor and tissue plasmino-
gen activator (16). Over a median followup period of 48
months, all patients who developed vascular complica-
tions of myocardial infarction, stroke, or deep venous
thrombosis had elevated urinary 11-dehydro-TXB2 ex-
cretion (16). Further evidence for the importance of
eicosanoid production in patients with aPL comes from
in vitro studies that demonstrate increased platelet
TXA2 production and aggregation when platelets are
cultured with b2-glycoprotein I and ACA (17).
The patients described herein had elevated uri-
nary metabolites of systemic TXA2 and PGI2. This
finding corroborates studies demonstrating that platelet
activation is present in patients with aPL (16). The
increased excretion of 2,3-dinor-6-keto PGF1a in these
patients is consistent with the concept that the produc-
tion of PGI2 is an important restraint on the excessive
activation of platelets. It also suggests that patients with
a known prothrombotic state and elevated platelet
TXA2 production may be at risk for thrombosis when
selective COX-2 inhibitors are administered.
Three of these patients had reduced levels of free
protein S antigen (patient 1 21%, patient 2 26%, patient
Table 3. Temporal relationship between initiation of cyclooxygenase 2 inhibition treatment and development of thrombotic symptoms
Patient 1 Patient 2 Patient 3 Patient 4
Duration of treatment
prior to symptoms
2 weeks (2 doses) 1 week 2 days (3 doses) 2–5 months*
Prescribed dosage 200 mg twice daily
as needed
100 mg twice daily 200 mg once or
twice daily
200 mg twice daily
* Symptoms attributed to vasculitis 2 months after initiation of treatment in this patient may, in retrospect, have been due to thrombosis.
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4 40%; normal 43–132%); this was not measured in
patient 3. Protein S is a required cofactor for activated
protein C to function as an anticoagulant. We suspect
that in these patients, reduced free protein S resulted
from the inflammatory state that elevated C4b-binding
protein levels, leading to a shift of free protein S to the
complexed, inactive form. Although a reduced protein S
level alone may not have been sufficient to trigger
thrombus formation, when combined with other risk
factors it may have contributed to the clinical presenta-
tion.
Independent of the prothrombotic risk factors
described above, these patients also had abnormal vas-
cular endothelial cell function that could have interfered
with the constitutive anticoagulant nature of the endo-
thelium. The patients with SLE had active disease with
hypocomplementemia and elevated levels of anti-DNA
antibodies, suggesting circulating immune complexes.
The patient with SSc had reduced complement levels as
well. Patient 1 also smoked cigarettes and had evidence
of atherosclerotic disease by arteriography and by patho-
logic examination after embolectomy.
A causal relationship between the initiation of
treatment with a specific COX-2 inhibitor and these
thrombotic events cannot be established on the basis of
the available evidence, even though the temporal rela-
tionship is impressive and the pathophysiologic rationale
well-founded. These findings are, however, consistent
with a hypothesis that thrombosis is an adverse conse-
quence of inhibition of prostacyclin biosynthesis in pa-
tients with a prothrombotic disorder. Additional evi-
dence would be needed to support or refute this
hypothesis. Certainly these observations, together with the
knowledge that COX-2 inhibitors selectively block prosta-
cyclin biosynthesis, suggest the need for heightened surveil-
lance of the consequences of specific COX-2 inhibition in
patients with diseases that predispose to thrombosis.
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